Inclusion Criteria:

        All of the following must apply at the time of enrollment:

          1. Patients with an advanced solid tumour (defined as incurable locally advanced or
             metastatic disease and excluding any haematologic malignancy).

             Tumour is positive for Lewis Y expression by immunohistochemistry - defined as a
             staining of ≥ 10 % of tumour cells positive for LeY expression. For the purposes of
             tumour screening, where possible the most recently available tumour sample should be
             utilised. A new biopsy is not mandatory where archival tissue is available, but may be
             considered.

          2. Patient is ≥18 years of age.

          3. Patient has an ECOG performance status of 0 - 1

          4. Patient has provided written confirmation of informed consent on participant
             information and consent form

          5. Life expectancy of ≥ 12 weeks

          6. Patient has adequate organ function satisfying all of the following:

               -  Liver: bilirubin <1.5x upper limit of normal (ULN) unless patient has known
                  Gilbert's syndrome;

               -  AST/ALT ≤2.5 x ULN except in patients with known liver metastases where
                  AST/ALT≤5.0

               -  Kidney: either serum creatinine <1.5x ULN or creatinine clearance > 50ml/min.
                  Creatinine clearance is either derived using the Cockcroft-Gault formula or may
                  be measured by 24 hour urine collection or nuclear medicine assessment.

               -  Lung: Adequate pulmonary function defined by SaO2 >91% on room air and ≤ grade I
                  dyspnoea.

               -  Cardiac: LVEF ≥ 40% as confirmed by echocardiogram or multiple uptake gated
                  acquisition (MUGA)

               -  Adequate bone marrow reserve as defined as:

                    -  Absolute neutrophil count (ANC) ≥ 1.0 x 10e9/L

                    -  Absolute lymphocyte count ≥ 0.5 x 10e9/L

                    -  Platelets ≥ 100 x 10e9/L

                    -  Haemoglobin >80g/L

                    -  WCC <30 x 10e9/L

          7. Patient is deemed capable and willing to undergo the planned study procedures in the
             view of the principal investigator.

          8. Women of childbearing potential (defined as all women physiologically capable of
             becoming pregnant) and all male participants must agree to use highly effective
             methods of contraception for one year following LeY CART therapy.

          9. Patient has measurable disease as per RECIST 1.1.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from participation in this
        study:

          1. Patients with known active central nervous system (CNS) involvement by malignancy.
             Patients with previous treated and/or neurologically stable disease will be eligible.

          2. Prior chimeric antigen receptor T (CART) cell therapy

          3. Patient has been given chemotherapy and/or G-CSF in the last 4 weeks or is planned to
             receive such therapy prior to apheresis of PBMC. Patients can only receive cytotoxic
             drugs as per the schedule of treatment for this protocol.

          4. Patient has had immunosuppressive therapy within 4 weeks of apheresis. Therapeutic
             doses of steroids (defined as > 20 mg/day of Prednisolone (or equivalent) must be able
             to be stopped > 7 days prior to leukapheresis and 72 hours prior to LeY CART cell
             infusion Physiologic doses of steroid (e.g. Prednisolone <10mg or equivalent), topical
             and inhaled steroids are permitted.

          5. Patient who are eligible for potentially curative therapy

          6. Uncontrolled active or latent Hepatitis B or active Hepatitis C or HIV

          7. Patients with uncontrolled systemic fungal, bacterial, viral or other infection
             despite appropriate antibiotics.

          8. History or presence of active clinically relevant CNS pathology such as epilepsy,
             aphasia, severe brain injury, dementia, Parkinson's disease, cerebellar disease or
             psychosis.

          9. Radiation therapy within 2 weeks prior to registration

         10. Patient has an active haematologic malignancy (any lymphoma, leukaemia, multiple
             myeloma or myelodysplastic syndrome)

         11. Patient has a history of significant pulmonary disease (including radiation
             pneumonitis) or known, biopsy proven autoimmune inflammatory disease of the
             gastrointestinal tract.

         12. Unstable angina or myocardial infarct within 6 months prior to screening.

         13. Patient has known clinically significant autoimmune disease with positive serology for
             RHF (>20kU/L) or ANA (titre >1:40).

         14. Women of child bearing potential (WOCBP) who are unwilling or unable to use an
             effective method of contraception to avoid pregnancy for the entire study period and
             for at least 12 months after completion of study treatment.

         15. Women who are pregnant or breastfeeding.

         16. Men who are unwilling or unable to use an acceptable method of contraception for the
             entire study period and for at least 12 months after completion of study treatment if
             their sexual partners are WOCBP.

         17. Patient has a serious uncontrolled medical disorder, psychological or social factors
             that which would impair the ability to receive protocol therapy and follow up.